VALCYTE

Valcyte is administered in adults to prevent cytomegalovirus (CMV) infection that may occur after heart, kidney, or pancreas organ transplantation. This medication is also used to treat CMV eye infections in adults with acquired immunodeficiency syndrome (AIDS).

For the prevention of CMV disease in transplant recipients: Adults who have undergone heart or kidney-pancreas transplantation should take 900 milligrams (mg) (two 450 mg tablets) once daily, starting within 10 days of transplantation and continuing until 100 days post-transplant.

Hazard Statements: H340 – May cause genetic defects. H350 – May cause cancer. H360FD – May impair fertility and damage the unborn child.

Valcyte can lower white blood cell, red blood cell, and platelet counts. Regular blood tests may be necessary to monitor these cell levels while taking Valcyte. Based on test results, your doctor may adjust your dosage or advise discontinuation. Valcyte may also carry a risk of cancer.

This medication may lead to kidney failure, particularly in elderly patients with existing kidney issues.

CMV infection may be asymptomatic in healthy individuals but can pose life-threatening risks in immunocompromised patients. Congenital cytomegalovirus infection can result in morbidity and even mortality. After initial infection, CMV often remains latent but can reactivate at any time.

Common side effects include low blood pressure, pancreatitis (inflammation of the pancreas), dry skin, and hair loss.

This is a generic drug. The average cost for 30 tablets of the generic (valganciclovir) in the 450MG strength is $217.80.

Valcyte (valganciclovir) carries a black box warning for hematologic toxicity, impairment of fertility, fetal toxicity, mutagenesis, and carcinogenesis. Please refer to Valcyte Prescribing Information for more details.

Valcyte (valganciclovir hydrochloride) is an antiviral medication used to treat CMV eye infections in patients with acquired immunodeficiency syndrome (AIDS). It is also used to prevent CMV infection in individuals who have undergone organ transplants, such as kidney, heart, or kidney-pancreas.

Valacyclovir is utilized to treat herpes virus infections, including herpes labialis (cold sores), herpes zoster (shingles), and herpes simplex (genital herpes) in adults. It is also prescribed for chickenpox and cold sores in children.

For the prevention of CMV disease: VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).

Oral valganciclovir, administered at a dose of 900 mg daily for 200 days following transplantation, is the current standard of care for CMV prophylaxis in CMV-seronegative kidney transplant recipients receiving organs from CMV-seropositive donors.

CMV infection can occasionally lead to mononucleosis or hepatitis (liver problems). Immunocompromised individuals who contract CMV may experience more severe symptoms affecting the eyes, lungs, liver, esophagus, stomach, and intestines. Infants born with CMV may develop brain, liver, spleen, lung, and growth complications.

The risk of CMV disease may also be elevated if you did not previously have the infection but received an organ transplant from a CMV-positive donor. A compromised immune system can further increase the risk of CMV disease.

Analyses, both univariate and multivariable, were used to assess the risk of late CMV infection and disease, as well as overall survival. Late CMV disease occurred in 26 out of 146 (17.8%) patients, with a median onset of 169 days post-transplantation (range, 96-784 days); the mortality rate was 46%.

During symptomatic CMV infection, kidney transplant recipients may experience prolonged fever, leukopenia, diarrhea, hepatitis, colitis, or allograft injury.

CMV is transmitted through direct contact with infectious body fluids, such as urine, saliva, blood, tears, semen, and breast milk. It can also be transmitted sexually and through transplanted organs and blood transfusions.

Valtrex (valacyclovir) and Valcyte (valganciclovir) are antiviral drugs used to treat different conditions. Valtrex is used to treat infections caused by shingles (herpes zoster), genital herpes (herpes simplex genitalis), and cold sores (herpes labialis).

While valacyclovir cannot cure shingles or genital herpes, it can alleviate pain, discomfort, and expedite the healing of sores. Valacyclovir is available only with a doctor’s prescription and is offered in tablet form.

No, both valacyclovir and acyclovir are considered safe. They are FDA-approved medications effective in treating shingles, HSV-1, HSV-2, and other forms of herpes.

Valganciclovir is used to manage symptoms of cytomegalovirus (CMV) retinitis, an eye infection occurring in individuals with acquired immunodeficiency syndrome (AIDS). Valganciclovir does not cure this eye infection but may help alleviate symptoms and prevent them from worsening. It is classified as an antiviral medication.

Valganciclovir is an antiviral drug. For additional information about Valcyte oral, please refer to its generic counterpart. The average cost for 30 tablets of the generic (valganciclovir) in the 450MG strength is $217.80.

Valcyte is utilized for the treatment of CMV Retinitis and CMV Prophylaxis and belongs to the purine nucleosides drug class. Its safety during pregnancy has not been established. Valcyte 450 mg is not classified as a controlled substance under the Controlled Substances Act (CSA).

Both are effectively the same drug. VALTREX is the brand name for valacyclovir. Your doctor will discuss which medication is the most suitable considering your health circumstances and condition which is being treated.

Valganciclovir belongs to the class of medications known as antivirals. It works by either preventing CMV disease or slowing the growth of CMV.

Valacyclovir begins to take effect as soon as it enters your system. Most people typically start experiencing benefits within two to three days, though this can vary depending on several factors, including the severity of the outbreak, the dosage, and how quickly the medication is taken upon recognizing an outbreak.

No, valganciclovir (Valcyte) is not an immunosuppressant. Therefore, valganciclovir (Valcyte) does not weaken the immune system. After transplantation, valganciclovir (Valcyte) is often prescribed alongside immunosuppressant medications to prevent CMV infection.

In some instances, CMV can lead to mononucleosis or hepatitis (liver problems). Immunocompromised individuals who contract CMV can experience more severe symptoms affecting the eyes, lungs, liver, esophagus, stomach, and intestines. Infants born with CMV may encounter complications involving the brain, liver, spleen, lungs, and growth.

Cyclophosphamide (Baxter’s Cytoxan) is recognized as one of the most potent immunosuppressive compounds. In small doses, it effectively treats conditions like systemic lupus erythematosus, autoimmune hemolytic anemias, granulomatosis with polyangiitis, and other autoimmune diseases.

Immunosuppressants, while beneficial in reducing the immune system’s harmful response against healthy tissues, also weaken the overall immune system, making individuals more susceptible to viral, bacterial, and fungal infections.